Companies / Health Care
TMO
Thermo Fisher Scientific
Life Sciences Tools & Services
Life Sciences Tools & ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health60
Growth31
Profitability60
Cash generation67
Balance sheet56
Dilution control87
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-26)9.1%Revenue growth (FY)3.9%Revenue CAGR (3y)-0.3%Gross margin—Operating margin17.4%Net margin15.0%Free cash flow margin14.1%R&D / revenue3.1%Stock comp / revenue0.7%Net debt / operating cash flow3.75xCurrent ratio1.89Diluted share count change-1.3%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $39.2B | $44.9B | $42.9B | $42.9B | $44.6B |
| Operating income | $10.0B | $8.4B | $6.9B | $7.3B | $7.7B |
| Net income | $7.7B | $7.0B | $6.0B | $6.3B | $6.7B |
| Operating cash flow | $9.3B | $9.2B | $8.4B | $8.7B | $7.8B |
| Capital expenditure | $2.5B | $2.2B | $1.5B | $1.4B | $1.5B |
| Free cash flow | $6.8B | $6.9B | $6.9B | $7.3B | $6.3B |
| R&D | $1.4B | $1.5B | $1.3B | $1.4B | $1.4B |
| Stock-based comp | $230M | $307M | $278M | $301M | $310M |
| Buybacks | $2.0B | $3.0B | $3.0B | $4.0B | $3.0B |
| Dividends | $395M | $455M | $523M | $583M | $636M |
| Cash | $4.5B | $8.5B | $8.1B | $4.0B | $9.9B |
| Total debt | $34.7B | $34.3B | $34.7B | $31.1B | $39.2B |
| Equity | $40.8B | $44.0B | $46.7B | $49.6B | $53.4B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.